drugset / Trial / NCT04998760
A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )
Non-randomizedParallel-groupOpen-labelTreatment
Summary
1\. This is a multi-center clinical study to evaluate dual mTORC1/2 inhibitor (ATG 008) or selective inhibitor of nuclear export compound (ATG-010) in combination with chemotherapy in patients with relapsed or metastatic ovarian cancer, endometrial cancer, and cervical cancer.
Timeline
- Start
- 2021-08-03
- Primary completion
- 2024-01-09
- Completion
- 2024-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ONATASERTIB | Small molecule | 30 mg | Oral |
| Subject | Selinexor | Other / unclassified | 30 mg | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |